The Impact of Probiotics on Gut Health in Individuals with Irritable Bowel Syndrome: A Randomized Controlled Trial

Project Abstract

Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. The use of probiotics has gained significant attention as a potential therapeutic intervention for improving gut health in individuals with IBS. This randomized controlled trial aims to investigate the impact of probiotics on gut health in individuals diagnosed with IBS. The study will evaluate the efficacy of probiotics in alleviating IBS symptoms, improving quality of life, and modulating gut microbiota composition. The research design involves a randomized controlled trial with a sample size of 100 participants diagnosed with IBS. Participants will be randomly assigned to either the probiotic intervention group or the placebo control group. The intervention group will receive a specific strain of probiotics daily for a period of 12 weeks, while the control group will receive a placebo. The primary outcomes include changes in IBS symptoms, such as abdominal pain, bloating, and bowel habits, assessed using standardized questionnaires. Secondary outcomes will focus on alterations in gut microbiota composition, inflammatory markers, and quality of life measures. The study methodology encompasses a comprehensive assessment of participants at baseline, including clinical evaluations, dietary assessments, and stool sample collection for microbiota analysis. Participants will be monitored closely throughout the intervention period, with regular follow-up visits to evaluate treatment adherence and symptom progression. Statistical analysis will be conducted to compare outcomes between the probiotic intervention and placebo control groups. The discussion of findings will focus on the efficacy of probiotics in improving gut health and alleviating IBS symptoms. The results will provide valuable insights into the potential mechanisms of action of probiotics in modulating gut microbiota and reducing gastrointestinal symptoms in individuals with IBS. Implications for clinical practice and future research directions will be discussed in detail. In conclusion, this research project aims to contribute to the growing body of evidence supporting the use of probiotics as a viable treatment option for individuals with IBS. The findings of this study have the potential to inform clinical practice guidelines and improve the management of gut health in individuals with gastrointestinal disorders.

Project Overview